TY - JOUR
T1 - Phase II prospective trial “Give Me Five” short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion
T2 - the impact of toxicity on quality of life (AIRC IG-13218)
AU - Marvaso, Giulia
AU - Gugliandolo, Simone Giovanni
AU - Bellerba, Federica
AU - Gandini, Sara
AU - Corrao, Giulia
AU - Volpe, Stefania
AU - Rojas, Damaris Patricia
AU - Riva, Giulia
AU - Zerini, Dario
AU - Pepa, Matteo
AU - Fodor, Cristiana Iuliana
AU - La Rocca, Eliana
AU - Pricolo, Paola
AU - Alessi, Sarah
AU - Petralia, Giuseppe
AU - Mistretta, Francesco Alessandro
AU - Cambria, Raffaella
AU - Cattani, Federica
AU - De Cobelli, Ottavio
AU - Orecchia, Roberto
AU - Jereczek-Fossa, Barbara Alicja
N1 - Funding Information:
SGG was partially Supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), by Project IG-14300 “Carbon ions boost followed by pelvic photon intensity-modulated radiotherapy for high-risk prostate cancer,” registered at ClinicalTrials.gov (NCT02672449). The study was also supported by Project IG-13218 “Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion,” registered at ClinicalTrials.gov (NCT01913717). The sponsors did not play any role in the study design, collection, analysis, and interpretation of data, nor in the writing of the manuscript, nor in the decision to submit the manuscript for publication.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediate-risk prostate cancer treated with extreme hypofractionated radiotherapy (RT) and simultaneous boost to the intraprostatic lesion. The aim of the study is to identify clinically meaningful information through the analysis of validated questionnaires testing gastrointestinal (GI) and genitourinary (GU) RT-related toxicity and their impact on quality of life (QoL). At the end of RT treatment, clinical assessment and prostate-specific antigen (PSA) measurements were performed every 3 months for at least 2 years and GI and GU toxicities were evaluated contextually. QoL of enrolled patients was assessed by International Prostate Symptoms score (IPSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 (EORTC QLQ-C30), EORTC QLQ prostate specific (QLQ-PR25), and sexual activity by International Index of Erectile Function (IIEF-5). Patients’ score changes were calculated at the end of RT, at one month after RT and at 12 and 24 months. Sixty-five prospectively enrolled patients were analyzed. Extensive analysis of different QoL assessments showed that patients’ tolerance was satisfactory across all the considered time points, with no statistically significant change of QoL from baseline compared to that before RT. Overall survival and biochemical progression-free survival at 2-years were of 98% and 97%, respectively. Despite the toxicity of extreme hypofractionation was low and tumor control was encouraging, a longer follow-up is necessary to confirm our findings. The increasing dose to the dominant intraprostatic lesion does not worsen the RT toxicity and consequently does not affect patients’ QoL, thus questioning the possibility of an even more escalated treatment.
AB - As part of the AIRC IG-13218 (NCT01913717), we analyzed data from patients with low- and intermediate-risk prostate cancer treated with extreme hypofractionated radiotherapy (RT) and simultaneous boost to the intraprostatic lesion. The aim of the study is to identify clinically meaningful information through the analysis of validated questionnaires testing gastrointestinal (GI) and genitourinary (GU) RT-related toxicity and their impact on quality of life (QoL). At the end of RT treatment, clinical assessment and prostate-specific antigen (PSA) measurements were performed every 3 months for at least 2 years and GI and GU toxicities were evaluated contextually. QoL of enrolled patients was assessed by International Prostate Symptoms score (IPSS), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire—Core 30 (EORTC QLQ-C30), EORTC QLQ prostate specific (QLQ-PR25), and sexual activity by International Index of Erectile Function (IIEF-5). Patients’ score changes were calculated at the end of RT, at one month after RT and at 12 and 24 months. Sixty-five prospectively enrolled patients were analyzed. Extensive analysis of different QoL assessments showed that patients’ tolerance was satisfactory across all the considered time points, with no statistically significant change of QoL from baseline compared to that before RT. Overall survival and biochemical progression-free survival at 2-years were of 98% and 97%, respectively. Despite the toxicity of extreme hypofractionation was low and tumor control was encouraging, a longer follow-up is necessary to confirm our findings. The increasing dose to the dominant intraprostatic lesion does not worsen the RT toxicity and consequently does not affect patients’ QoL, thus questioning the possibility of an even more escalated treatment.
KW - Clinical trial
KW - Dominant intraprostatic lesion
KW - Extreme hypofractionation
KW - Prostate cancer
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85088638738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088638738&partnerID=8YFLogxK
U2 - 10.1007/s12032-020-01397-3
DO - 10.1007/s12032-020-01397-3
M3 - Article
C2 - 32725443
AN - SCOPUS:85088638738
VL - 37
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 8
M1 - 74
ER -